X4 Pharmaceuticals, Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter report; the provided filing does not give a clear set of Q4-only financial results.
Business context
X4 is a clinical-stage biopharmaceutical company focused on therapies targeting the CXCR4 pathway. Its lead candidate, oral mavorixafor, was in a global Phase 3 trial for WHIM syndrome at year-end. The company also began Phase 1b trials in severe congenital neutropenia (SCN) and Waldenström macroglobulinemia (WM). X4 completed its merger with Arsanis on March 13, 2019; for accounting purposes, X4 was the acquirer, so 2019 results include acquired Arsanis assets and activities from the merger date, while the reported historical results are those of X4.
Financial and operating metrics
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $30.2 million | $20.3 million |
| General and administrative expense | $17.6 million | $8.7 million |
| Total operating expenses | $51.7 million | $29.1 million |
| Net loss | $52.8 million | $33.3 million |
| Net loss per share, basic and diluted | $4.63 | $79.15 |
| Net cash used in operating activities | $48.1 million | $25.4 million |
No meaningful operating margin is reported because the company had no product sales. The sharp per-share loss change is affected by the merger, reverse stock split, share conversions and a substantially different weighted-average share count, and should not be read as a direct measure of operating improvement.
- Cash and liquidity: At December 31, 2019, cash and cash equivalents were $126.2 million; restricted cash was $1.9 million. Total cash, cash equivalents and restricted cash were $128.1 million. Management said available liquidity was expected to cover operating, investing and debt-service needs for at least 12 months from the March 12, 2020 filing date.
- Debt: Hercules principal outstanding was $20.0 million at year-end (carrying value, including accretion and net of discount, was $20.1 million). The rate was 8.75% at year-end; the reported effective annual rate was 10.9%. Interest-only payments run through January 2022, with principal payments beginning in February 2022 and maturity on July 1, 2023. The loan is secured by substantially all assets other than intellectual property, subject to stated exceptions, and includes financial and operating covenants.
- Financing and cash flow: Financing activities provided $140.7 million, principally from $139.4 million net proceeds from equity, prefunded-warrant and warrant offerings and $9.8 million net loan proceeds, partly offset by repayment of FFG loans. Investing activities provided $27.2 million, primarily reflecting $26.4 million of cash acquired in the merger.
- Margins and balance sheet: Total assets were $160.7 million and total liabilities $31.5 million at year-end. The company reported an accumulated deficit of $132.0 million. There was no current portion of long-term debt at year-end.
Material changes versus the prior comparable period
- Net loss increased by $19.5 million, operating expenses rose by $22.6 million, and operating cash use increased by $22.6 million compared with 2018. Management attributed higher R&D costs mainly to mavorixafor’s Phase 3 development and increased personnel; higher G&A reflected staffing, public-company, insurance, compliance and legal costs.
- In March 2019, the merger brought in $26.4 million of cash and restricted cash and added Arsanis assets and liabilities. The combined company changed its name to X4 Pharmaceuticals and effected a 1-for-6 reverse stock split.
- X4 raised $139.4 million net in 2019 through public offerings. It also refinanced its Hercules debt and repaid approximately $6.5 million of FFG loans in September, recording a $0.6 million debt-extinguishment loss.
- A $3.9 million loss was recorded when acquired Arsanis research programs were transferred to third parties; the charge included $4.9 million of derecognized in-process R&D assets, partly offset by $1.0 million of upfront fees.
Outlook, management commentary and risks
- Management expected top-line Phase 3 WHIM data in the second half of 2021 and initial SCN and WM trial data in the second half of 2020. These are forward-looking expectations, not results or guarantees.
- Mavorixafor received FDA Breakthrough Therapy Designation for adults with WHIM syndrome and orphan drug designations in the U.S. and Europe. Designations do not assure approval or a faster development or review process.
- The company expects substantial continuing R&D spending and losses and does not expect significant product revenue in the foreseeable future. It stated that additional capital will be needed; future financing may dilute shareholders or require unfavorable debt, collaboration or licensing terms.
- Key risks include clinical-trial execution and enrollment in rare diseases, regulatory approval, uncertain patient-market estimates, competition, intellectual-property protection, and reliance on single third-party manufacturers for mavorixafor drug substance and finished capsules. X4 had no redundant supply source in place.
- Under the July 2019 Abbisko agreement, X4 licensed mavorixafor oncology rights in Greater China. Potential milestone and royalty payments are contingent and were not recognized as revenue; the filing describes potential milestones of up to $208 million assuming development in six indications.
- The company signed a seven-year lease for new Allston office space expected to replace its Cambridge headquarters in 2020. At year-end, the lease had not commenced for accounting purposes; planned rent and construction costs add future cash commitments.
- The independent auditor issued an unqualified opinion on the financial statements and highlighted that additional financing will be required. Management stated its disclosure controls and internal control over financial reporting were effective as of December 31, 2019. The auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether the 4WHIM Phase 3 trial meets its primary endpoint and whether the company’s expected data timing or regulatory pathway changes.
- Cash burn, restricted and lender-accessible cash, Hercules covenant compliance, and financing runway relative to management’s 12-month estimate.
- Current enrollment, safety and efficacy updates for the SCN and WM trials, and whether the projected data milestones were achieved.
- Manufacturing capacity and contingency plans for the single-source mavorixafor suppliers, including commercial-scale supply readiness.
- Potential dilution from outstanding warrants and future financing, and the conditions required for Abbisko milestone and royalty revenue.